| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2004 | WO2004073688A1 Drug delivery from embolic agents |
| 09/02/2004 | WO2004073685A1 Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
| 09/02/2004 | WO2004073684A2 Lipophilic drug delivery vehicle and methods of use thereof |
| 09/02/2004 | WO2004073683A1 Use of pvp-iodine liposomes for treatment of atopic dermatitis |
| 09/02/2004 | WO2004073682A2 Use of pvp-iodine liposomes for treatment of herpes |
| 09/02/2004 | WO2004073681A1 Medicaments |
| 09/02/2004 | WO2004073680A1 Ointment of droplet-dispersion type |
| 09/02/2004 | WO2004073679A1 Reinforced urethral suppository |
| 09/02/2004 | WO2004073674A1 Tea-tree oil-based preparation, methods for the production and use thereof |
| 09/02/2004 | WO2004073658A2 Isoflavone derivatives |
| 09/02/2004 | WO2004073654A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 09/02/2004 | WO2004073653A2 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | WO2004073648A2 Composition and methods for inhibiting cell survival |
| 09/02/2004 | WO2004073645A2 Inhibition of olfatory neurosensory function of treat eating disorders and obesity |
| 09/02/2004 | WO2004073643A2 Estradiol metabolites for the treatment of pulmonary hypertension |
| 09/02/2004 | WO2004073639A2 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 09/02/2004 | WO2004073638A2 Method of lowering body temperature with (s)-2,3-benzodiazepines |
| 09/02/2004 | WO2004073637A2 Compositions comprising a defined polysaccharide component |
| 09/02/2004 | WO2004073636A2 Compositions comprising a polysaccharide component and one or more coating layers |
| 09/02/2004 | WO2004073635A2 Compositions comprising a plurality of particles or agglomerates having a defined particle size |
| 09/02/2004 | WO2004073634A2 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 09/02/2004 | WO2004073632A2 Rapid absorption selective 5-ht agonist formulations |
| 09/02/2004 | WO2004073631A2 Combination therapy for the treatment of neoplasms |
| 09/02/2004 | WO2004073628A2 Novel compounds |
| 09/02/2004 | WO2004073627A2 Novel therapeutic method and compositions for topical administration |
| 09/02/2004 | WO2004073623A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | WO2004073622A2 Novel therapeutic method and compositions for topical administration |
| 09/02/2004 | WO2004073620A2 The selective and specific preparation of discrete peg compounds |
| 09/02/2004 | WO2004073619A2 Ccr8 antagonists |
| 09/02/2004 | WO2004073617A2 Tertiary amine functional complex polyester polymers |
| 09/02/2004 | WO2004073614A2 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | WO2004073612A2 Estrogen receptor modulators |
| 09/02/2004 | WO2004073611A2 Compounds for the treatment of metabolic disorders |
| 09/02/2004 | WO2004073610A2 Estrogen receptor modulators |
| 09/02/2004 | WO2004073608A2 Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
| 09/02/2004 | WO2004073607A2 Use of steroids to treat ocular disorders |
| 09/02/2004 | WO2004073606A2 Sulfonamide derivatives as ppar modulators |
| 09/02/2004 | WO2004073605A2 Skin peeling composition and method |
| 09/02/2004 | WO2004073604A2 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity |
| 09/02/2004 | WO2004073603A2 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/02/2004 | WO2004073602A2 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 09/02/2004 | WO2004073601A2 Process for the preparation of hexacyclic camptothecin derivatives |
| 09/02/2004 | WO2004073599A2 Inhibitors of hepatitis c virus, compositions and treatments using the same |
| 09/02/2004 | WO2004073597A2 Bioadhesive liquid composition which is substancially free of water |
| 09/02/2004 | WO2004073593A2 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications |
| 09/02/2004 | WO2004073592A2 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 09/02/2004 | WO2004073584A2 Cystitis treatment with high dose chondroitin sulfate |
| 09/02/2004 | WO2004073583A2 Use of antimuscarinic drugs for preventing the onset of epilepsy |
| 09/02/2004 | WO2004073420A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 09/02/2004 | WO2004073375A2 Podophyllotoxin derivatives as antitumor agents |
| 09/02/2004 | WO2004062645B1 Microspheres containing amphotericin b |
| 09/02/2004 | WO2004062569A3 Cardiolipin compositions their methods of preparation and use |
| 09/02/2004 | WO2004060361A3 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
| 09/02/2004 | WO2004058730A3 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 09/02/2004 | WO2004058168A3 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| 09/02/2004 | WO2004056362A3 8-trialkysyloxy-2-methyl-9-phenyl-7-0 xo-7,8,9,10- tetrahydroimidazo ‘1,2-h! ‘1,7! naphthyridines |
| 09/02/2004 | WO2004056324A3 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| 09/02/2004 | WO2004054600B1 Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus |
| 09/02/2004 | WO2004054505A3 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
| 09/02/2004 | WO2004052904A3 Novel semisynthetic macrolide antibiotics of the azalide series |
| 09/02/2004 | WO2004052313A3 Anti-infectives |
| 09/02/2004 | WO2004052285A3 Fat regulation |
| 09/02/2004 | WO2004052284A3 Treatment of diabetes |
| 09/02/2004 | WO2004052076A3 Mixed esters of dicarboxylic acids for use as pigment dispersants |
| 09/02/2004 | WO2004050647A3 Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof |
| 09/02/2004 | WO2004050057A3 An exopolysaccharides delivery system for active molecules |
| 09/02/2004 | WO2004043378A3 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 09/02/2004 | WO2004043375A3 Pharmaceutical compositions and methods of using taxane derivatives |
| 09/02/2004 | WO2004043358A3 Formulations of low solubility bioactive agents and processes for making the same |
| 09/02/2004 | WO2004041256A3 Safe chemical uncouplers for the treatment of obesity |
| 09/02/2004 | WO2004041190A3 Composition for the treatment of macular degenration |
| 09/02/2004 | WO2004037187A3 Metal-containing materials, compositions and methods |
| 09/02/2004 | WO2004026319A3 Pharmaceutical compositions increasing camp useful for the treatment of cancers |
| 09/02/2004 | WO2004024066A3 Method of treating diabetes and related conditions |
| 09/02/2004 | WO2004018000A3 Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents |
| 09/02/2004 | WO2004014851A3 Tyrosine kinase inhibitors |
| 09/02/2004 | WO2004014320A3 Methods of using beta glucan as a radioprotective agent |
| 09/02/2004 | WO2004014291B1 Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| 09/02/2004 | WO2004002421A3 Method for the treatment of multiple sclerosis |
| 09/02/2004 | WO2003101375A3 Immunostimulatory oligonucleotides and uses thereof |
| 09/02/2004 | WO2003099786A3 Aromatic sulfones and their medical use |
| 09/02/2004 | WO2003086312A3 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof |
| 09/02/2004 | WO2003084539A3 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 09/02/2004 | WO2003084344A3 Method of improving absorption of vitamin e by a pet animal |
| 09/02/2004 | WO2003077867A3 Naltrexone hydrochloride compositions |
| 09/02/2004 | WO2003063910A3 β-HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER |
| 09/02/2004 | WO2003049698A8 Substituted hydrazones as inhibitors of cyclooxygenase-2 |
| 09/02/2004 | WO2003032906A3 Delivery of poorly soluble drugs |
| 09/02/2004 | WO2003026617A8 (ester)-lysolecithins in liposomes |
| 09/02/2004 | WO2003000200A3 β-2'-OR 3'-HALONUCLEOSIDES |
| 09/02/2004 | WO2002092589A3 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments |
| 09/02/2004 | WO2002074289A3 Antitumor compositions containing taxane derivatives |
| 09/02/2004 | US20040172665 Compositions and methods for treating enzyme deficiency |
| 09/02/2004 | US20040172112 Methods for treating prostatitis |
| 09/02/2004 | US20040171881 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 09/02/2004 | US20040171876 Processes for the production of alpha-difluoromethyl ornithine (DFMO) |
| 09/02/2004 | US20040171875 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171844 Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 09/02/2004 | US20040171843 Process for preparing losartan potassium with improved flow ability |